At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
(+)-SJ000557733 (SJ733)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase 2a Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of (+)-SJ000557733 (SJ733) With or Without Cobicistat in Adult Patients With Acute, Uncomplicated Malaria Over a 42 Day Period
In Brief
A Phase 2 clinical trial evaluating (+)-SJ000557733 (SJ733) for Malaria, Falciparum and Malaria, Vivax. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This Phase 2a trial recruits adult patients with uncomplicated P. vivax or P. falciparum blood-stage malaria mono-infection. The study drug SJ733 will be administered to examine its antimalarial efficacy, safety, and tolerability. This study also evaluates whether or not a fixed dose of the pharmacoenhancer cobicistat when given in combination with SJ733 significantly improves drug efficacy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria, Falciparum, Malaria, Vivax
CountriesPeru
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartApr 2021
Primary CompletionApr 2022
TodayJul 2026
First PostedJan 14, 2021
Enrollment StartApr 14, 2021
Primary CompletionApr 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.5 years ago
Interventions
(+)-SJ000557733 (SJ733)drug
Anti-Malarial